122772-02-5

Basic information

• Product Name: C₁₂H₁₇N₃O₃S
• CAS NO: 122772-02-5
• Molecular Weight: 283.351
• Mol File: 122772-02-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: C₁₂H₁₇N₃O₃S(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₂H₁₇N₃O₃S(122772-02-5)
• EPA Substance Registry System: C₁₂H₁₇N₃O₃S(122772-02-5)

Safety Data

• Hazardous Substances Data: 122772-02-5(Hazardous Substances Data)

Upstream product

• 3943-77-9 ethyl veratrate 
• 93-07-2 Veratric acid 
• 542-85-8 Ethyl isothiocyanate 
• 41764-74-3 3,4-dimethoxybenzohydrazide 

Downstream Products

• 1015595-96-6 2-[4-ethyl-5-(3,4-dimethoxyphenyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-1-phenylethanone 
• 122772-20-7 5-(3,4-Dimethoxy-phenyl)-4-ethyl-4H-[1,2,4]triazole-3-thiol 

Relevant articles and documents

Design, synthesis and molecular docking of new N-4-piperazinyl ciprofloxacin-triazole hybrids with potential antimicrobial activity

New N-4-piperazinyl ciprofloxacin-triazole hybrids 6a-o were prepared and characterized. The in vitro antimycobacterial activity revealed that compound 6a experienced promising antimycobacterial activity against Mycobactrium smegmatis compared with the reference isoniazide (INH). Additionally, compound 6a exhibited broad spectrum antibacterial activity against all the tested strains either Gram-positive or Gram-negative bacteria compared with the reference ciprofloxacin. Also, compounds 6g and 6i displayed considerable antifungal activity compared with the reference ketoconazole. DNA cleavage assay of the highly active compounds 6c and 6h showed a good correlation between the Mycobactrium cleaved DNA gyrase assay and their in vitro antimycobactrial activity. Moreover, molecular modeling studies were done for the designed ciprofloxacin derivatives to predict their binding modes towards Topoisomerase II enzyme (PDB: 5bs8).

New nitric oxide donating 1,2,4-triazole/oxime hybrids: Synthesis, investigation of anti-inflammatory, ulceroginic liability and antiproliferative activities

A series of novel nitric oxide (NO) donating triazole/oxime hybrids was prepared and evaluated for their anti-inflammatory activity. Most of the tested compounds showed significant anti-inflammatory activity using carrageenan-induced rat paw edema method compared to indomethacin. Calculation of the ulcer indices and histopathological investigation indicated that the prepared NO-donating oximes exhibited less ulcerogenicity compared to their intermediate ketones and indomethacin. The NO-donating oxime 6i revealed significant activity against renal cancer A498 cell lines with 50.52 cell growth inhibition.